Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Los efectos del antagonismo de orexina en la extinción del miedo en el TEPT

2 de noviembre de 2026 actualizado por: VA Office of Research and Development

PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep. Treatments for PTSD are based on fear extinction principles in which individuals are repeatedly exposed a feared cue in the absence of danger, resulting in diminishing physiological reactions, a process believed to underlie recovery from PTSD. Studies suggest that orexin, a wake-promoting neuropeptide, may enhance fear extinction. This study will examine whether suvorexant, a selective orexin-receptor antagonist, will enhance fear extinction in Veterans with PTSD and insomnia. Finding a role for orexins in fear extinction will support the rationale for its further evaluation in the treatment of PTSD. Suvorexant is an accessible, safe medication that has been well-established in treating insomnia. It has outstanding promise for treating common and distressing symptoms in Veterans with PTSD.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

PTSD is a common consequence of combat manifested in part by trauma-related arousal and reactivity, seen in increased startle and impaired sleep that result from central and autonomic nervous system alterations. Impaired fear extinction may explain prolonged physiological alterations in PTSD. Preclinical evidence suggests that orexin, a wake-promoting neuropeptide, may be a shared mechanism underlying both sleep and fear extinction. While rodent studies have shown that pharmacological manipulations that block orexin in rodents facilitate fear extinction, no studies have tested this in humans with PTSD.

In line with the CSRD Combined Proof of Concept and Clinical Trial Merit Review Award mechanism, the investigators propose a proof-of-concept study leading to a clinical trial. During the initial phase, the investigators will develop and establish feasibility of the task and recruitment in 40 eligible participants with PTSD and insomnia. The task will involve a home-based multi-day remote fear conditioning experimental study, in which Veterans with PTSD and insomnia will receive nightly doses of suvorexant or placebo following extinction training over the subsequent 6 nights. Primary Aims of the proof of concept will be to: 1) establish remote fear conditioning procedures collaboratively with Veteran stakeholders; 2) evaluate enrollment, tolerability, adherence, and retention; 3) demonstrate fear conditioning and extinction learning using remote procedures; and 4) determine task feasibility of the home-based remote fear conditioning task. Go/No go milestones include: 1) the ability to enroll and randomize 40 participants by the end of month 23; 2) most participants (> 80%) will take medication as prescribed over 7 nights; 3) no SAEs during the course of treatment as determined by the data monitoring committee review (DMC); 4) < 10% of post-randomization participants will drop out (<4 participants), resulting in 36 individuals who complete all study procedures by month 23; 5) successful demonstration of measurement of fear conditioning (greater skin conductance (SC) responses to CS+ cues vs CS- cues) and fear extinction (differential SC responses to CS+ and CS- cues that diminish over trials) in the combined sample; 6) feasibility of the remote task demonstrated by <15% data loss due to recording issues (e.g., technical malfunction or UCS non-response in <6 participants).

If milestones are met, the investigators will advance to a clinical mechanistic trial to evaluate suvorexant in facilitating fear extinction using a double-blind randomized, placebo-controlled experimental design in Veterans with PTSD and insomnia. A total of 120 male and female Veterans with PTSD and insomnia will be randomized to either the suvorexant or placebo condition (n=60 in each condition). Participants will be trained in multi-day remote procedures involving fear conditioning (Day 1) and extinction 3 days later (Day 4), followed by 10 mg. suvorexant or placebo. A flexible dose titration of suvorexant (10-20 mg.) or matching placebo will be administered over the next 6 nights. Participants will then undergo extinction retention and fear reinstatement tests one week after extinction (Day 11). Primary outcome measures will be differential skin conductance responses to CS+ and CS- cues during extinction retention and reinstatement phases.

Primary Aims of the Clinical Trial will be: 1) To examine whether suvorexant facilitates fear extinction, seen as greater extinction retention compared to placebo. 2) To examine whether the facilitative effects of suvorexant are more resistant to reinstatement compared to placebo. Pending an effect of suvorexant on fear extinction retention and reinstatement, the investigators will evaluate whether improvement in insomnia mediates these effects. In-home sleep recording (including both sleep EEG and indices of sleep-disordered breathing) and sleep diary measures will be examined as secondary mediators. Greater improvement in sleep quality will partially account for greater extinction retention and less reinstatement. If successful, the proposed study will offer proof-of-concept data and meaningful guidance for future studies of suvorexant as an augmentation co-treatment in exposure therapy.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40120

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Sabra S Inslicht, PhD
  • Número de teléfono: 3341 (415) 221-4810
  • Correo electrónico: sabra.inslicht@va.gov

Ubicaciones de estudio

    • California
      • San Francisco, California, Estados Unidos, 94121-1563
        • Reclutamiento
        • San Francisco VA Medical Center, San Francisco, CA
        • Contacto:
          • Sabra S Inslicht, PhD
          • Número de teléfono: 3341 (415) 221-4810
          • Correo electrónico: sabra.inslicht@va.gov
        • Investigador principal:
          • Sabra S Inslicht, PhD
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29401-5703
        • Aún no reclutando
        • Ralph H. Johnson VA Medical Center, Charleston, SC
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • (same for Phase 1 and Phase 2):

    • men and women
    • a history of US military service
    • capable of reading and understanding English
    • able to provide written informed consent
  • Criterion A event meets DSM-5 criteria and occurred during military service, including combat and military sexual trauma

  • Chronic full PTSD diagnosis >3 months duration as indexed by CAPS-5 at screening, and CAPS-5 score > 30

  • Insomnia indicated by insomnia severity index (ISI) score > 14

  • Subjects on non-exclusionary medications, and must be on a stable dose for at least 4 weeks prior to randomization, including Selective Serotonin Reuptake Inhibitors (SSRIs, e.g.,):

    • sertraline
    • paroxetine
    • fluoxetine
    • fluvoxamine
    • citalopram
    • escitalopram
  • Serotonin-norepinephrine reuptake inhibitors (SNRIs; e.g.):

    • Desvenlafaxine
    • Duloxetine
    • Levomilnacipran
    • Venlafaxine
  • For subjects who are in psychotherapy, treatment must be stable for 6 weeks

  • Women of child-bearing potential must not be pregnant or have plans for pregnancy or breastfeeding during the study and must use a medically acceptable method of birth control

Exclusion Criteria:

  • Moderate or severe DSM-5 alcohol or cannabis use disorder in the last 3 months

    • Mild alcohol use disorder with abstinence of 30 days will be allowed
    • Mild marijuana use disorder will be allowed with abstinence for one week prior to participation
    • Any other DSM-5 drug use disorder in the last 3 months will be excluded
  • Lifetime bipolar disorder I or II, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, or major depressive disorder with psychotic features

  • Exposure to trauma in the last 3 months

  • Use of exclusionary antidepressant (trazodone, mirtazapine, doxepin, tricyclics), mood stabilizers (e.g., lithium), antipsychotic medication

  • Prominent suicidal or homicidal ideation or any suicidal behavior in the past 3 months on the Columbia Suicide Severity Rating Scale (C-SSRS) or increased risk of suicide that necessitates additional therapy or inpatient treatment

  • Pre-existing moderate sleep apnea or positive screen for sleep apnea by type III device (AHI>15) in the absence of adherence to effective treatment (such as CPAP or oral device)

  • Night shift work or extreme morning or evening tendencies in order to avoid the impact of circadian factors on subjective and objective sleep measures

  • Neurologic disorder or systemic illness affecting CNS function

  • Chronic or unstable medical illness, including:

    • unstable angina
    • myocardial infarction within the past 6 months
    • congestive heart failure
    • preexisting hypotension or orthostatic hypotension
    • heart block or arrhythmia
    • chronic renal or hepatic failure
    • pancreatitis
    • severe chronic obstructive pulmonary disease
  • History of severe traumatic brain injury as assessed by the Ohio State University Traumatic Brain Injury Identification Method (OSU-TBI ID)

  • Uncorrected hearing impairment

  • Mild cognitive impairment assessed by the Montreal Cognitive Assessment (MOCA)

  • Pregnancy, breastfeeding and/or refusal to use effective birth control (for women)

  • Previous adverse reaction to a hypnotic

  • Current use of benzodiazepines, strong inhibitors of CYP3A, or Digoxin

    • The investigators will require that all participants do not consume heavy amounts of alcohol per week (>7 drinks for women, >14 drinks for men) or use illicit drugs for one week prior to participation

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Suvorexant

Suvorexant pills (10-20 milligrams)

Suvorexant pills (10-20 milligrams)

Comparador de placebos: Placebo

Matching placebo pills

Matching placebo pills

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Enrollment
Periodo de tiempo: Month 4-23

Goal of enrolling 40 individuals to achieve a total of 30 completers by the end of month 23.

Month 4-23
Medication Adherence
Periodo de tiempo: Month 4-23

Pill count and adherence to instructions over 7 study nights

Month 4-23
Side effect reports
Periodo de tiempo: Month 4-23

Serious Adverse Events (SAEs)

Month 4-23
Post-randomization drop out
Periodo de tiempo: Month 4-23

Post-randomization drop-out rates

Month 4-23
Fear conditioning and extinction
Periodo de tiempo: Month 4-23

Fear conditioning (greater SC responses to CS+ cues vs CS- cues) and fear extinction (differential SC responses to CS+ and CS- cues that diminish over repeated trials) in the combined sample

Month 4-23
Rates of technical malfunction
Periodo de tiempo: Month 4-23

Rates of technical malfunction (SC levels that are missing or <.02 microsiemens) and or non-responding to the UCS (e.g., SCR<.05 microsiemens)

Month 4-23
Electrodermal Activity
Periodo de tiempo: Years 2-7

Differential SC responses to CS+ and CS- cues during extinction retention and 2) during reinstatement.

Years 2-7

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Insomnia Severity Index
Periodo de tiempo: Years 2-7

Self-reported sleep

Years 2-7
Sleep Electroencephalogram (EEG)
Periodo de tiempo: Years 2-7

Total sleep time, rapid eye movement (REM)

Years 2-7

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Sabra S Inslicht, PhD, San Francisco VA Medical Center, San Francisco, CA

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de julio de 2026

Finalización primaria (Estimado)

1 de marzo de 2032

Finalización del estudio (Estimado)

30 de junio de 2032

Fechas de registro del estudio

Enviado por primera vez

16 de enero de 2025

Primero enviado que cumplió con los criterios de control de calidad

16 de enero de 2025

Publicado por primera vez (Actual)

23 de enero de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir